Effects of long-term administration of octreotide in portal vein-stenosed rats.
The hemodynamic effects of long-term administration of octreotide in portal hypertension has not been established. In addition, whether long-term octreotide treatment prevents the development of portosystemic shunts has not yet been evaluated. Hence, the current study was undertaken to evaluate the effects of long-term administration of octreotide in rats with portal vein stenosis. Immediately after portal vein stenosis or sham operation, rats were given either a long-term octreotide administration of 100 micrograms/kg or a placebo every 12 hours by subcutaneous injection for 14 consecutive days. Systemic hemodynamics and regional blood flows, degree of mesenteric-systemic shunts, and plasma glucagon concentrations were measured after the final dose of octreotide or placebo. A fifth group of portal vein-stenosed rats received hemodynamic and plasma glucagon measurements after 1-day octreotide treatment given at 14 days after surgery. Long-term octreotide treatment modified the hyperdynamic circulation without affecting the degree of mesenteric-systemic shunts, and 1-day octreotide treatment decreased portal tributary blood flow without affecting the portal pressure, systemic hemodynamics, and degree of mesenteric-systemic shunts. Plasma glucagon levels were decreased in portal vein-stenosed rats receiving either long-term or 1-day octreodtide compared with rats receiving placebo. In contrast, chronic octreotide treatment did not affect any of the hemodynamic values or plasma glucagon levels in sham-operated rats. In conclusion, long-term administration of octreotide modified in part the development of portal hypertension and hyperdynamic circulation in portal vein-stenosed rats without affecting the degree of mesenteric-systemic shunts.
Lin
H C
HC
Department of Medicine, Veterans General Hospital, Taipei, Taiwan.
Yang
M C
MC
Hou
M C
MC
Li
S M
SM
Huang
Y T
YT
Yu
P C
PC
Tsai
Y T
YT
Lee
S D
SD
D000704:Analysis of Variance; D000818:Animals; D003251:Constriction, Pathologic; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005934:Glucagon / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects; D006975:Hypertension, Portal / Q000517:prevention & control*; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology*; D017082:Portal Pressure / Q000187:drug effects; D011169:Portal Vein / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013152:Splanchnic Circulation / Q000187:drug effects
D005765:Gastrointestinal Agents; D005934:Glucagon; D015282:Octreotide